Volibris 5mg &10mg Tablets
PDF Leaflet Revision Date: 22 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of pulmonary arterial hypertension (PAH).
Dosage (summary)
5 mg once daily, may increase to 10 mg if tolerated; 10 mg once daily with tadalafil.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential teratogenic effects.
Key Drug Interactions
- Ciclosporin A
- Ketoconazole
- Rifampicin
- Sildenafil
- Warfarin
Contraindications
- Hypersensitivity to ambrisentan
- Pregnancy
- Severe hepatic impairment
- Idiopathic pulmonary fibrosis
Common side effects
- Anaemia
- Headache
- Palpitations
- Flushing
- Fluid retention
Counselling Points
- Monitor for signs of hepatic injury
- Avoid in pregnancy
- Report any signs of anaemia
Serious warnings
- Hepatic injury
- Auto-immune hepatitis
- Potential for hypotension
Important Disclaimer
The Volibris 5mg &10mg Tablets professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
